Lung trials now recruiting patients
Our lung cancer trials are focused on the benefits and side effects of radiotherapy.
TROG 16.03 (CORE) - this study aims to show that the addition of SBRT (stereotactic body radiotherapy) to standard of care improves progression free survival for patients with extra-cranial oligiometastatic disease that has spread from their lung, breast and/or prostate cancer
Primary sponsor: Institute of Cancer Research (ICR)
Collaborating groups: TROG
TROG 16.01 (NIVORAD) - A randomised phase II trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.
Primary sponsor: The University of Sydney
Collaborating groups: ALTG and TROG
TROG 11.03 (P_LUNG) - this study investigates whether adding chemotherapy to a short course of radiotherapy results in a greater improvement in symptoms and overall wellbeing compared with using a short course of radiotherapy alone in patients with Non-Small Cell Lung Cancer (NSCLC).
Primary sponsor: TROG